Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · IEX Real-Time Price · USD
1.450
-0.030 (-2.03%)
At close: Apr 26, 2024, 4:00 PM
1.400
-0.050 (-3.45%)
After-hours: Apr 26, 2024, 7:30 PM EDT
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CMPX stock have an average target of 9.00, with a low estimate of 8.00 and a high estimate of 10. The average target predicts an increase of 520.69% from the current stock price of 1.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CMPX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Apr 16, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +451.72% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +589.66% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Aug 3, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Mar 16, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
13.31M
EPS This Year
-0.49
from -0.33
EPS Next Year
-0.51
from -0.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 35.6M | 230.4M | 558.3M | 907.8M |
| Avg | n/a | 13.3M | 102.9M | 283.7M | 452.9M |
| Low | n/a | n/a | 12.8M | 83.6M | 154.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,630.2% | 442.4% | 220.0% |
| Avg | - | - | 673.0% | 175.6% | 59.7% |
| Low | - | - | -3.9% | -18.8% | -45.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.47 | -0.41 | 0.20 | 1.79 | 2.55 |
| Avg | -0.49 | -0.51 | -0.16 | 0.36 | 1.13 |
| Low | -0.52 | -0.77 | -0.42 | -0.14 | 0.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 602.7% |
| Avg | - | - | - | - | 212.5% |
| Low | - | - | - | - | -97.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.